List view / Grid view
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
5 April 2016 | By Victoria White
If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations...
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
16 September 2015 | By Victoria White
Blue Latitude has been reappointed to provide Janssen with strategic support and creative marketing services for their brand teams in the EMEA region...
10 September 2015 | By Victoria White
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma...
3 July 2015 | By Victoria White
The EC has approved Janssen’s Stelara for the treatment of moderate-to-severe plaque psoriasis in adolescent patients from the age of 12 years and older...
27 May 2015 | By Victoria White
The CHMP has recommended approval of STELARA for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 and older...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
10 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis...
7 June 2012 | By Publicis Life Brands Resolute
New efficacy and safety data...
